- Home
- CMMB vs APCX Comparison
CMMB vs APCX Comparison
Compare CMMB & APCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CMMB
- APCX
- Stock Information
- Founded
- CMMB 2004
- APCX 2006
- Country
- CMMB Israel
- APCX United States
- Employees
- CMMB N/A
- APCX N/A
- Industry
- CMMB Biotechnology: Pharmaceutical Preparations
- APCX Finance: Consumer Services
- Sector
- CMMB Health Care
- APCX Finance
- Exchange
- CMMB Nasdaq
- APCX Nasdaq
- Market Cap
- CMMB 15.8M
- APCX 15.8M
- IPO Year
- CMMB N/A
- APCX N/A
- Fundamental
- Price
- CMMB $1.51
- APCX $0.52
- Analyst Decision
- CMMB Strong Buy
- APCX
- Analyst Count
- CMMB 3
- APCX 0
- Target Price
- CMMB $5.67
- APCX N/A
- AVG Volume (30 Days)
- CMMB 229.7K
- APCX 278.2K
- Earning Date
- CMMB 11-07-2024
- APCX 11-12-2024
- Dividend Yield
- CMMB N/A
- APCX N/A
- EPS Growth
- CMMB N/A
- APCX N/A
- EPS
- CMMB N/A
- APCX N/A
- Revenue
- CMMB N/A
- APCX $462,000.00
- Revenue This Year
- CMMB N/A
- APCX $1,315.48
- Revenue Next Year
- CMMB N/A
- APCX N/A
- P/E Ratio
- CMMB N/A
- APCX N/A
- Revenue Growth
- CMMB N/A
- APCX 3.59
- 52 Week Low
- CMMB $0.42
- APCX $0.44
- 52 Week High
- CMMB $2.55
- APCX $3.36
- Technical
- Relative Strength Index (RSI)
- CMMB 43.28
- APCX 25.30
- Support Level
- CMMB $1.29
- APCX $0.54
- Resistance Level
- CMMB $1.78
- APCX $0.62
- Average True Range (ATR)
- CMMB 0.16
- APCX 0.08
- MACD
- CMMB -0.05
- APCX -0.02
- Stochastic Oscillator
- CMMB 36.73
- APCX 16.06
About CMMB Chemomab Therapeutics Ltd.
Chemomab Therapeutics Ltd is a clinical-stage biotech company, focusing on the discovery and development of therapeutics for fibrosis-related diseases with large unmet needs. The company's candidate, CM-101, is a monoclonal antibody that targets CCL24 and was shown to interfere with the underlying biology of liver, skin and lung fibrosis using a novel and differentiated mechanism of action. CM-101 has demonstrated the potential to treat multiple severe and life threatening fibrotic and inflammatory diseases. It is advancing three Phase 2 clinical trials in parallel for CM-101 treating rare fibrotic conditions.
About APCX AppTech Payments Corp.
AppTech Payments Corp is a FinTech company utilizing various payment processing and digital banking technologies to complement core merchant services capabilities. The company's patented and proprietary software will provide progressive and adaptable products that are available through a suite of synergistic offerings directly to merchants, banking institutions, and business enterprises. It is developing a secure digital payments and banking platform that powers commerce experiences for clients and customers. Based upon industry standards for payment and banking protocols, the company will offer standalone products and fully integrated solutions that deliver unparalleled payments, banking, and financial services experiences.